Argo Biopharma Named to Fast Company's Annual List of the World’s Most Innovative Companies of 2026

Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE

Argo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer

Argo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting

Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)

Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference